DMDaiki Muramatsu

Daiki Muramatsu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daiki Muramatsu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181

    by Moeko Noguchi-Shinohara, Daiki Muramatsu, Ayano Shima, Yasuhiro Sakashita, Yasutake Tada, Hiroki Yamaguchi, Junji Komatsu, Tokuhei Ikeda, Kenjiro Ono


  • Gadolinium enhancement of the cauda equina in a case of familial ALS with p.S135G SOD1 mutation

    by Sumika Nomizo, Junji Komatsu, Ayano Shima, Daiki Muramatsu, Keitaro Matsubara, Ichiro Nozaki, Moeko Noguchi-Shinohara, Ayumi Nishiyama, Naoki Suzuki, Masashi Aoki, et al.

    Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive degeneration of the upper and lower motor neurons, resulting in muscle weakness and atrophy. G...

  • Cover Image

    by Daiki Muramatsu, Takahiro Watanabe‐Nakayama, Mayumi Tsuji, Kenichi Umeda, Sadao Hikishima, Hiroto Nakano, Yasuhiro Sakashita, Tokuhei Ikeda, Hiroki Konno, Noriyuki Kodera, et al.

  • Open Access

    ALZ ‐801 prevents amyloid β‐protein assembly and reduces cytotoxicity: A preclinical experimental study

    by Daiki Muramatsu, Takahiro Watanabe‐Nakayama, Mayumi Tsuji, Kenichi Umeda, Sadao Hikishima, Hiroto Nakano, Yasuhiro Sakashita, Tokuhei Ikeda, Hiroki Konno, Noriyuki Kodera, et al.

    Alzheimer's disease (AD) is the most prevalent age‐related neurodegenerative disorder, mainly characterized by amyloid β (Aβ) accumulation in the brain. Numerous new agents are currently undergoing clinical trials as disease‐modifying therapies (DMTs) targeting Aβ. ALZ‐801 is a promising candidate DMT for AD, with a phase 3 trial of ALZ‐801 ongoing specifically for apolipoprotein E (APOE) ε4 homozygous patients with early‐stage AD. This study aimed to examine the effects of ALZ‐801 on Aβ assembly and explore its toxicological profile. Thioflavin T (ThT) assays and two imaging modalities—transmission electron microscopy (TEM) and high‐speed atomic force microscopy (HS‐AFM)—were used to evaluate ALZ‐801's effects on Aβ assembly. To assess the effect of ALZ‐801 on Aβ 42 ‐induced cytotoxicity, 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assays and lactate dehydrogenase (LDH) assays were performed. ThT assays revealed increased lag time and decreased fluorescence in the presence of ALZ‐801, confirming inhibition of Aβ 42 fibril formation, as confirmed by TEM. Real‐time observation using HS‐AFM revealed that ALZ‐801 inhibited the formation of Aβ 42 fibril from low‐molecular‐weight (LMW)‐Aβ 42 in the presence of Aβ 42 seeds. HS‐AFM also revealed that globular aggregates from LMW‐Aβ 42 were significantly larger with ALZ‐801, with few fibrils noted. MTT and LDH assays indicated that ALZ‐801 prevented LMW‐Aβ 42 ‐induced cytotoxicity but did not reduce cytotoxicity induced by high‐molecular‐weight‐Aβ 42 . ALZ‐801 can inhibit Aβ 42 aggregation by preventing both nucleus formation and fibril elongation, while promoting large globular oligomer formation, and can significantly reduce LMW‐Aβ 42 ‐induced cytotoxicity. These findings underscore the potential of ALZ‐801 as an effective DMT for APOE ε4 homozygous patients with AD.